1 n excellent platform from which to construct
antidiarrheals.
2 AEs were managed with comedications (e.g.
antidiarrheals),
abemaciclib dose holds (61.7%), and/or
3 gesting that both antiparasitic activity and
antidiarrheal activity can be obtained with a single vac
4 In conclusion, ATRA may act as an
antidiarrheal agent by increasing DRA expression via the
5 In this study, nifuroxazide, an
antidiarrheal agent identified as an inhibitor of Stat3,
6 Antidiarrheal agents (including loperamide, diphenoxylat
7 ommon adverse effect but was manageable with
antidiarrheal agents and dose modification.
8 Other
antidiarrheal agents are under investigation.
9 nal nonretentive fecal soiling (encopresis),
antidiarrheal agents can increase the consistency of sto
10 CLT and related drugs may serve as novel
antidiarrheal agents in humans and animals.
11 cept for the utility of this model to screen
antidiarrheal agents.
12 pharmacophore for the construction of other
antidiarrheal agents.
13 incontinence (biofeedback, sphincteroplasty,
antidiarrheal and laxative medications, and sacral nerve
14 Education,
antidiarrheals and biofeedback therapy are the mainstay
15 polyamine analogues and their evaluation as
antidiarrheals are described.
16 The chloride channel-blocking
antidiarrheal drug crofelemer dose-dependently inhibited
17 It may be clinically useful as an
antidiarrheal drug.
18 , synthesis, and testing of a novel class of
antidiarrheal drugs based on a tetraamine pharmacophore
19 In addition to
antidiarrheal drugs, fiber supplements may improve incon
20 nt Group study was undertaken to confirm the
antidiarrheal effect of sucralfate.
21 siologic studies examining how Zn exerts its
antidiarrheal effect.
22 sis, mechanism of action by patch-clamp, and
antidiarrheal efficacy in closed-loop and suckling mouse
23 The
antidiarrheal functions were unique to CXCR2, since othe
24 In many patients, a trial of
antidiarrheal medication is warranted before colonoscopy
25 ounced among the 63 persons who did not take
antidiarrheal medications or antimicrobial agents (12 vs
26 nts with microscopic colitis will respond to
antidiarrheal medications or to anti-inflammatory therap
27 Fewer
antidiarrheal medications were required in the study gro
28 ith Campylobacter infection who did not take
antidiarrheal medications, persons with ciprofloxacin-re
29 omatic treatment includes cholestyramine and
antidiarrheal medications.
30 d moxifloxacin and the antacid Maalox or the
antidiarrheal Pepto-Bismol using a tail-suspended (TS) r
31 Subsequent patients received
antidiarrheal prophylaxis (ADP) to define a second MTD,
32 Strict adherence to an
antidiarrheal regimen of diphenhydramine/loperamide sign
33 to 9% was noted with strict adherence to an
antidiarrheal regimen of loperamide and diphenyldramine.
34 olony-stimulating factor (G-CSF) and maximal
antidiarrheal support.